Table 1.
Clinico-pathological features
| 0- 49 | 20 cases | 16% | |
|---|---|---|---|
| 50-59 | 35 | 27,5% | |
| Age (years) | 60-69 | 50 | 39% |
| > 70 | 22 | 17,5% | |
| Mass beneath the areola | 119 cases | 93,5% | |
| Clinical complaint | Gynecomastia | 5 | 4% |
| Paget'disease | 3 | 2,5% | |
| Tx | 2 cases | 1,5% | |
| T1 | 6 | 5% | |
| Primary Tumor | T2 | 18 | 14% |
| T3 | 22 | 17% | |
| T4 | 79 | 62,5% | |
| Nx | 9 | 7,1% | |
| Lymph node | N0 | 16 | 12,5% |
| N1 | 70 | 55,2% | |
| N2 | 32 | 25,2% | |
| Metastasis | M0 | 90 | 71% |
| M1 | 37 | 29% | |
| I | 6 | 5% | |
| IIA | 8 | 6,1 | |
| Stage | IIB | 12 | 9,6 |
| III | 64 | 50,3% | |
| IV | 37 | 29% | |
| IDC: | 122 | 96% | |
| SBR 2 ou 3 | 100 | 82% | |
| Histology | With Paget's disaese | 2 | 1,6% |
| ILC | 1 | 0,8% | |
| ND | 2 | 1,6% | |
| Lymph node status | pN0 | 29 | 35,5% |
| pN+ | 54 | 64,5% | |
| Hormone receptors | RE | 39/61 | 64% |
| RP | 39/61 | 64% | |
Ductal infiltrating carcinoma (IDC); Invasive lobular carcinoma (ILC); not defined (ND) Estrogen receptor (ER); progesterone receptor (PR)